Drug Guidance for Subsidy 01/09/2023 Pralsetinib for treating RET fusion-positive locally advanced or metastatic non-small-cell lung cancer
Post Marketing Information DHCPL 29/10/2024 Gavreto® (pralsetinib) - new warning and precaution of severe and fatal infections